Axial Therapeutics
Clinical-stage CNS bio-pharmaceutical company focused on small molecule therapies.
Launch date
Employees
Market cap
-
Enterprise valuation
€135—203m (Dealroom.co estimates Oct 2021.)
Waltham Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | Spinout | ||
$19.2m | Series A | ||
$10.0m | Series B | ||
$37.3m | Series C | ||
Total Funding | €60.4m |
Related Content
Recent News about Axial Therapeutics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.